Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study
Won-Seog Kim(Samsung Medical Center), Yok‐Lam Kwong(Queen Mary Hospital), Ming Yao(Anhui University), Dae Seog Heo(Seoul National University), Jun Zhu(Peking University), Su‐Peng Yeh(China Medical University), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Hyeon‐Seok Eom(National Cancer Center), Jin Seok Kim(University of Ulsan), Ming Qi(Janssen (United States)), Huiqiang Huang(Sun Yat-sen University), Lijia Zhang(Fuzhou University), Grace Gao(Northumbria University)
Cited by 8
Related Papers
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342
Polyethylene glycol-grafted poly-l-lysine as polymeric gene carrier
|Journal of Controlled Release|1998|337